Day: March 2, 2020

Fourth Quarter ResultsTotal revenues of $52.1 million, a 4% year-over-year increaseNet loss of $(2.2) million and loss per diluted share of $(0.05)Adjusted EBITDA of $8.3 million and a 16% Adjusted EBITDA margin$11.2 million in cash on hand and $12.9 million of total debt as of December 31, 2019HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) — NCS Multistage Holdings, Inc. (NASDAQ: NCSM) (the “Company,” “NCS,” “we” or “us”), a leading provider of highly engineered products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies, today announced its results for the quarter and year ended December 31, 2019.Financial ReviewFourth Quarter 2019 Financial ResultsRevenues were $52.1 million for the quarter ended December 31, 2019, which was an increase of 4% compared to the...

Fourth quarter GAAP earnings per diluted share changed to $0.09 from $0.10Full year GAAP loss per diluted share changed to $0.47 from $0.42Fourth quarter non-GAAP earnings per diluted share remained $0.46Full year non-GAAP earnings per diluted share changed to $1.21 from $1.24PLEASANTON, Calif., March 02, 2020 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced an update to its previously announced financial results for the three months and full year ended December 31, 2019. After the release of its financial results on February 6, 2020, the Company identified and made certain immaterial corrections and related tax effects...

CAMBRIDGE, Mass. and BEIJING, China, March 02, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights, anticipated upcoming milestones, and financial results for the fourth quarter and full year of 2019.“Having co-founded BeiGene in 2010 with Dr. Xiaodong Wang, this anniversary year promises to continue the momentum and trajectory from our recent catalysts, including the read-outs of two Phase 3 trials, approvals for BRUKINSA and tislelizumab in the United States and China, respectively, and closing on our collaboration with Amgen, which is already off to a productive start as we advance the commercialization...

Company Initiates 2020 Full Year GuidanceBoard Authorizes $10 Million Share Repurchase ProgramLAS VEGAS, March 02, 2020 (GLOBE NEWSWIRE) — Everi Holdings Inc. (NYSE:EVRI) (“Everi” or the “Company”), a premier provider of gaming products, financial technology and player loyalty solutions to the gaming industry, today reported financial results for the fourth quarter and full year ended December 31, 2019.Fourth Quarter 2019 HighlightsRevenue increased 22% to a quarterly record $145.2 millionNet loss was $4.1 million, or $(0.05) per diluted share, inclusive of a $6.4 million pre-tax charge related to a litigation settlement, compared to net income of $4.2 million, or $0.06 per diluted share, in the prior yearAdjusted EBITDA, a non-GAAP financial measure, increased 16% to $63.2 millionFree Cash Flow, a non-GAAP financial measure, increased...

~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington’s DiseaseExpected to Occur Around the End of the First Quarter of 2020 ~~ Strong Balance Sheet Expected to Fund Operations into 2022 ~LEXINGTON, Mass. and AMSTERDAM, March 02, 2020 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2019 and highlighted recent progress across its business.“The past year was marked by strong execution in our pivotal, Phase III HOPE-B study of etranacogene dezaparvovec in hemophilia B for which we achieved full enrollment and expect to announce top-line data before the end of...

– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 –– Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 –– Clinical trial milestones and data readouts in 1H20 – – Company to host conference call and webcast today at 4:30 p.m. ET –BOSTON, March 02, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial results for the fourth quarter and year ended December 31, 2019 and provided a corporate update.“In the 16 months since forging our corporate independence, we have advanced all our clinical programs, licensed critical intellectual property, recruited key personnel to the Company and Board, and fortified our financial position,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer. “In...

ANDOVER, Mass., March 02, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter and year ended December 28, 2019.Recent HighlightsNet revenue of $6.1 million in the fourth quarter of 2019, representing 71% growth compared to the fourth quarter of 2018OCS Heart FDA Panel scheduled for April 16, 2020Initiated the OCS Heart DCD program enabling patients access to a broader pool of donor hearts“2019 was a momentum building year for Transmedics in which we built a solid foundation for growth and made meaningful progress across our three OCS products,” said Waleed Hassanein, M.D., President and Chief Executive Officer. “Through 2020...